Transcaval Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation Using a Dedicated Self-Expanding Device.
TAVR
alternative access
aortic regurgitation
electrosurgery
transcaval
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
04
12
2023
accepted:
18
12
2023
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
11
4
2024
Statut:
epublish
Résumé
Novel dedicated devices allow transcatheter treatment of pure aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System was introduced as the first dedicated and on-label AR transcatheter aortic valve replacement system, implementing a locator-based and calcium-independent anchoring mechanism. Here, we present the first-in-human transcatheter aortic valve replacement for pure AR via a transcaval access in a patient with prohibitive alternative arterial accesses.
Identifiants
pubmed: 38601848
doi: 10.1016/j.jaccas.2024.102320
pii: S2666-0849(24)00102-5
pmc: PMC11002802
doi:
Types de publication
Case Reports
Langues
eng
Pagination
102320Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Dr Curio has received research grant support from Boston Scientific. Dr Wienemann has received travel support from JenaValve. Dr Baldus has received lecture fees from JenaValve; and lecture and speaker fees from Edwards Lifesciences. Dr Adam has received personal honoraria /speaker fees from Abbott, Boston Scientific, Edwards Lifesciences, JenaValve, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.